UNLABELLED: Twelve children with documented Prader-Labhart-Willi syndrome were treated with human growth hormone (24 U/m2/week) during 1 year. The children were divided into three groups: group 1: overweight and prepubertal (n=6, age 3.8-7.0 years); group 2: underweight and prepubertal (n=3, age 0.6-4.1 years); group 3: pubertal (n=3, age 9.2-14.6 years). In group 1, height increased from -1.7 SD to -0.6 SD, while weight decreased from 1.1 SD to 0.4 SD, with a dramatic drop in weight for height from 3.8 SD to 1.2 SD. Hand length increased from -1.5 SD to -0.4 SD and foot length from -2.5 SD to -1.4 SD. Body fat, measured by dual X-ray energy absorptiometry, dropped by a third, whereas muscle mass increased by a fourth. Physical capability (Wingate test) improved considerably. The children were reported to be much more active and capable. In group 2, similar changes were seen, but weight for height increased, probably because muscle mass increase exceeded fat mass decrease. Changes in group 3 were similar as in group 1, even though far less distinct. CONCLUSION: Growth hormone treatment in Prader-Labhart-Willi syndrome led to dramatic changes: distinct increase in growth velocity, height and muscle mass, as well as an improvement in physical performance. Fat mass and weight for height decreased in the initially overweight children, and weight for height increased in underweight children.
RCT Entities:
UNLABELLED: Twelve children with documented Prader-Labhart-Willi syndrome were treated with humangrowth hormone (24 U/m2/week) during 1 year. The children were divided into three groups: group 1: overweight and prepubertal (n=6, age 3.8-7.0 years); group 2: underweight and prepubertal (n=3, age 0.6-4.1 years); group 3: pubertal (n=3, age 9.2-14.6 years). In group 1, height increased from -1.7 SD to -0.6 SD, while weight decreased from 1.1 SD to 0.4 SD, with a dramatic drop in weight for height from 3.8 SD to 1.2 SD. Hand length increased from -1.5 SD to -0.4 SD and foot length from -2.5 SD to -1.4 SD. Body fat, measured by dual X-ray energy absorptiometry, dropped by a third, whereas muscle mass increased by a fourth. Physical capability (Wingate test) improved considerably. The children were reported to be much more active and capable. In group 2, similar changes were seen, but weight for height increased, probably because muscle mass increase exceeded fat mass decrease. Changes in group 3 were similar as in group 1, even though far less distinct. CONCLUSION:Growth hormone treatment in Prader-Labhart-Willi syndrome led to dramatic changes: distinct increase in growth velocity, height and muscle mass, as well as an improvement in physical performance. Fat mass and weight for height decreased in the initially overweight children, and weight for height increased in underweight children.
Authors: W P Robinson; A Bottani; Y G Xie; J Balakrishman; F Binkert; M Mächler; A Prader; A Schinzel Journal: Am J Hum Genet Date: 1991-12 Impact factor: 11.025
Authors: M Angulo; M Castro-Magana; B Mazur; J A Canas; P M Vitollo; M Sarrantonio Journal: J Pediatr Endocrinol Metab Date: 1996 May-Jun Impact factor: 1.634
Authors: S Loche; M Cappa; P Borrelli; A Faedda; A Crinò; S G Cella; R Corda; E E Müller; C Pintor Journal: Clin Endocrinol (Oxf) Date: 1987-08 Impact factor: 3.478
Authors: Merlin G Butler; Jennifer Sturich; Jaehoon Lee; Susan E Myers; Barbara Y Whitman; June-Anne Gold; Virginia Kimonis; Ann Scheimann; Norma Terrazas; Daniel J Driscoll Journal: Pediatrics Date: 2011-03-14 Impact factor: 7.124
Authors: Aaron L Carrel; Susan E Myers; Barbara Y Whitman; Jens Eickhoff; David B Allen Journal: J Clin Endocrinol Metab Date: 2010-01-08 Impact factor: 5.958
Authors: Merlin G Butler; Jaehoon Lee; Devin M Cox; Ann M Manzardo; June-Anne Gold; Jennifer L Miller; Elizabeth Roof; Elisabeth Dykens; Virginia Kimonis; Daniel J Driscoll Journal: Clin Pediatr (Phila) Date: 2016-02-03 Impact factor: 1.168